TherapeuticsMD (TXMD) Net Cash Flow Growth (1y) (2011 - 2026)
TherapeuticsMD (TXMD) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -236.85% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -1,020.00% |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 35.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.05% |
| Dec 31, 2025 | 2,105.88% |
| Sep 30, 2025 | 1,507.04% |
| Jun 30, 2025 | -73.78% |
| Mar 31, 2025 | 405.24% |
| Dec 31, 2024 | 100.57% |
| Sep 30, 2024 | 98.82% |
| Jun 30, 2024 | 142.84% |
| Mar 31, 2024 | 97.37% |
| Dec 31, 2023 | 96.38% |
| Sep 30, 2023 | -130.98% |
| Jun 30, 2023 | 97.59% |
| Mar 31, 2023 | 62.31% |
| Dec 31, 2022 | -270.95% |
| Sep 30, 2022 | 395.64% |
| Jun 30, 2022 | -437.54% |
| Mar 31, 2022 | -140.41% |
| Dec 31, 2021 | 5,515.14% |
| Sep 30, 2021 | 80.75% |
| Jun 30, 2021 | 53.44% |